Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F., 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985.
Asano, M., Yukita, A., Matsumoto, T., Kondo, S., and Suzuki, H., 1995, Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor. Cancer Res. 55: 5296–5301.
Maeda, H., and Matsumura, Y., 1989, Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Sys. 6: 193–210.
Maeda, H., 1991, SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6:181–202.
Maeda, H., 1994, Polymer conjugated macromolecular drugs for tumor-specific targeting. In Polymer Site Specific Pharmacotherapy (A. J. Domb, eds.) John Wiley & Sons Ltd., New York, USA, pp. 95–116.
Maeda, H., Seymour, L., and Miyamoto, Y., 1992, Conjugation of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3: 351–362.
Courtice, F. C., 1963, The origin of lipoprotein. In Lymph and Lymphatic System (H. S. Meyersen, Chairman) Charles C. Thomas, Springfield, IL, USA, pp. 89–126.
Muggia, F. M., 1999, Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res. 5: 7–8.
Folkman, J., 1971, Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285: 1182–1186.
Folkman, J., and Shing, Y., 1992, Angiogenesis, J. Biol. Chem. 267: 10931–10934.
Maeda, H., Matsumura, Y., and Kato, H., 1988, Purification and identification of [hydroxyprolyl 3] bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263: 16051–16054.
Matsumura, Y., Kimura, M., Yamamoto, T., and Maeda, H., 1988, Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79: 1327–1334.
Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T., and Maeda, H., 1991, Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 82: 732–741.
Wu, J., Akaike, T., and Maeda, H., 1998, Modulation of enhanced vascular permeability in tumors by bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58: 159–165.
Maeda, H., Noguchi, Y., Sato, K., and Akaike, T., 1994, Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85: 331–334.
Doi, K., Akaike, T., Horie, M., Noguchi, Y., Fujii, S., Beppu, T., Ogawa, M., and Maeda, H., 1996, Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 77: 1598–1604.
Ferratra, N., and Henzel, W. J., 1989, Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161: 851–858.
Rosenthal, R. A., Megyesi, J. F., Henzel, W. J., Ferrara, N., and Folkman, J., 1990, Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 4: 53–59.
Leung, D. W., Cachianes, G., Kuang. W-J., Goeddel, D. V., and Ferrara, N., 1989, Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309.
Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connolly, D. T., 1989, Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309–1312.
Reichman, H. R., Farrell, C. L, and Del Maestro, F. R., 1986, Effect of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model. J. Neurosurg. 65: 233–237.
Wu, J., Akaike, T., Hayashida, K., Okamoto, T., Okuyama, A., and Maeda, H., 2001, Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn. J. Cancer Res. 92: 439–451.
Suzuki, M., Takahashi, T., and Sato, T., 1987, Medial regression and its functional significance in tumor-supplying host arteries. Cancer 59: 444–450.
Skinner, S. A., Tutton, P. J. M., and O’Brien, E., 1991, Microvascular architecture of experimental colon tumors in the rats. Cancer Res. 50: 2411–2417.
Kuruppu, D., Christophi, C., Maeda, H., and O’Brien, P. E., 2002, Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol. J. Surg. Res. 103: 47–54.
Matsumura, Y., and Maeda, H., 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46: 6387–6392.
Iwai, K., Maeda, H., and Konno, T., 1984, Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 44: 2115–2121.
Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., and Maeda, H., 1998, Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89: 307–314.
Iwai, K., Maeda, H., Konno, T., Matsumura, Y., Yamashita, R., Yamasaki, K., Hirayama, S., and Miyauchi, Y., 1987, Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res. 7: 321–328.
Maeda, H., Matsumoto, T., Konno, T., Iwai, K., and Ueda, M., 1984, Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on Smancs. J. Prot. Chem. 3: 181–193.
Maeda, H., Matsumura, Y., Oda, T., and Sasamoto, K., 1986, Cancer selective macromolecular therapeutics: tailoring of antitumor protein drugs. In Protein Tailoring. for Food and Medical Uses (R. E. Feeney and J. R. Whitaker, eds.) Marcel Dekker Inc., New York, USA, pp. 353–382.
Sawa, T., Sahoo, S. K., and Maeda H., 2002, Water-soluble polymer therapeutics with special emphasis on cancer chemotherapy. In Polymers in Medicine and Biotechnology (Ashady, eds.), Am. Chem. Soc., Washington D. C., Monograph, in press.
Suzuki, M., Hori, K., Abe, Z., Saito, S., and Sato, H., 1981, A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67: 663–669.
Li, C. J., Miyamoto, Y., Kojima, Y., and Maeda, H., 1993, Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67: 975–980.
Maeda, H., and Yamamoto, T., 1996, Pathogenic mechanisms induced by microbial proteases in microbial infections. Biol. Chem. Hoppe-Seyler. 377: 217–226.
Nakano, S., Mastukado, K., and Black, K. L., 1996, Increased brain tumor microvessel permeability after intracarotid bradkinin infusion is mediated by nitric oxide. Cancer Res. 56: 4027–4031.
Hu, D. E., and Fan, T. P., 1993, [Leu8]des-Arg9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br. J. Pharmacol. 109: 14–17.
Maeda, H., Wu, J., Okamoto, T., Maruo, K., and Akaike, T., 1999, Kallikrein-kinin in infection and cancer. Immunopharmacology. 43: 115–128.
Hori, K., Saito, S., Takahashi, H., Sato, H., Maeda, H., and Sato, Y., 2000, Tumorselective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn. J. Cancer Res. 91: 261–269.
Strausser, H. R., and Humes, J. L., 1975, Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in BALB/c mice. Int. J. Cancer 15: 724–730.
Trevisani, A., Ferretti, E., Capuzzo, A., and Tomasi, V., 1980, Elevated levels of prostaglandin E 2 in Yoshida hepatoma and the inhibition of tumor growth by nonsteroidal anti-inflammatory drugs. Br. J. Cancer 41: 341–347.
Greengberg, E. R., Baron, J. A., Freeman, D. H., Mandel, J. S. Jr, and Haile, R., 1993, Reduced risk of large-bowel adenomas among aspirin users. J. Natl. Cancer Inst. 85: 912–916.
Meyer, R. E., Shan, S., Deangelo, J., Dodge, R. K., Bonaventura, J., Ong. E. T., and Dewhirst, M. W., 1995, Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br. J. Cancer 71: 1169–1174.
Tozer, G. M., Prise, V. E., and Chaplin, D. J., 1997, Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine, Cancer Res. 57: 948–955.
Gallo, O., Masini, E., Morbidelli, L., Franchi, A., Fini-Storchi, I., Vergari, W. A., and Ziche, M., 1998, Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 90: 587–596.
Garcia-Cardena, G., and Folkman, J., 1998, Is there a role for nitric oxide in tumor angiogenesis. (Editorial) J. Natl Cancer Inst. 90: 560–561.
Jackson, J. R., Seed, M. P., Kirchen, C. H., Willoughby, D. A., and Winkler, J. D., 1997, The codependence of angiogenesis and chronic inflammation. FASEB J. 11: 457–465.
Maeda, H., Takishita, J., and Kanamaru, R., 1979, A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int. J. Pept. Protein Res. 14: 81–87.
Maeda, H., Ueda, M., Morinaga, T., and Matsumoto, T., 1985, Conjugation of poly(styrene-co-maleic acid) derivatives to antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem. 28: 455–461.
Konno, T., Maeda, H., Iwai K., Maki, S., Tashiro, S., Uchida, M., and Miyauchi, Y., 1984, Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54: 2367–2374.
Konno, T., Maeda, H., Iwai, K., Tashiro, S., Maki, S., Marinaga, T., Mochinaga, M., Hiraoka, T., and Yokoyama, I., 1983, Effect of arterial administration of highmolecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol. 19: 1053–1065.
Maki, S., Konno, T., and Maeda, H., 1985, Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56: 751–757.
Tsuchikya, K., Uchida, T., Kobayashi, M., Maeda, H., Konno, T., and Yamanaka, H., 2000, Tumor-targeted chemotherapy with SMANCS in Lipiodol for renal cell carcinoma: longer survival with larger size tumors. Urology 55: 495–500.
Maeda, H., and Miyamoto, Y., 1994, SMANCS approach — Oily formulation of protein drugs for arterial injection and oral administration. In Drug Absorption Enhancement: Concepts, Possibilities, Limitations, and Trends (A. G. De Boer, ed.) Harwood Academic Publishers, Chur, Switzerland, pp. 221–247.
Konno, T., and Maeda, H., 1987, Targeting chemotherapy of hepatocellular carcinoma: arterial administration of SMANCS/Lipiodol. In Neoplasms of the Liver (K. Okuda, K.G. Ishak, eds.), Springer-Verlag, Tokyo, Berlin, New York, pp. 343–352.
Konno, T., 1992, Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. Eur. J. Cancer 28: 403–409.
Maeda, H., and Konno, T., 1997, Metamorphosis of neocarzinostatin to SMANCS: chemistry, biology, pharmacology and clinical effect of the first prototype anticancer polymer therapeutic. In Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (H. Maeda, K. Edo and N. Ishida, eds.) Springer-Verlag, Tokyo, Berlin, New York, pp. 227–267.
Sawa, T., Wu, J., Akaike, T. and Maeda H., 2000, Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res. 60: 666–671.
Fang, J., Sawa, T., Akaike, T., and Maeda, H., 2002, Tumor-Targeted Delivery of PEGConjugated D-Amino Acid Oxidase for Antitumor Therapy via Enzymatic Generation of Hydrogen Peroxide. Cancer Res. 62: 3138–3143.
Sahoo, S. K., Sawa, T., Fang, J., Tanaka, S., Miyamoto, Y., Akaike, T., and Maeda H., 2002, Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 13: 1031–1038.
Doi, K., Akaike, T., Fujii, S., Tanaka, S., Ikebe, S., Beppu, N., Shibahara, T., Ogawa, S., and Maeda, H., 1999, Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br. J. Cancer 80: 1945–1954.
Tanaka, S., Akaike, T., Fang, J., Beppu, T., Ogawa, M., Tamura, F., Miyamoto, Y., and Maeda, H., 2002, Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br. J. Cancer (in press).
Maeda, H., Sawa, T., and Konno, T., 2001, Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Controlled Release 74: 47–61.
Maeda, H., 2002, Enhanced permeability and Retention (EPR) Effect: Basis for Drug Targeting to Tumor. In Biomedical Aspects of Drug Targeting (V. Muzykantov and V. Torchilin, eds.), Kluwer Academic Publishers, Dordrecht.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Fang, J., Sawa, T., Maeda, H. (2004). Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS. In: Maeda, H., Kabanov, A., Kataoka, K., Okano, T. (eds) Polymer Drugs in the Clinical Stage. Advances in Experimental Medicine and Biology, vol 519. Springer, Boston, MA. https://doi.org/10.1007/0-306-47932-X_2
Download citation
DOI: https://doi.org/10.1007/0-306-47932-X_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47471-2
Online ISBN: 978-0-306-47932-8
eBook Packages: Springer Book Archive